NCI Definition: Acute myeloid leukemias, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms arising as a result of the mutagenic effect of chemotherapy agents and/or radiation that are used for the treatment of neoplastic or non-neoplastic disorders. [1]

Therapy-related myeloid neoplasms most frequently harbor alterations in TP53, DNMT3A, TET2, ASXL1, and SRSF2 [2].

Most Commonly Altered Genes in Therapy-Related Myeloid Neoplasm

TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, DNMT3A Mutation, and TP53 Exon 5 Mutation are the most common alterations in therapy-related myeloid neoplasm [2].

Top Alterations in Therapy-Related Myeloid Neoplasm

Significant Genes in Therapy-Related Myeloid Neoplasm

ABL1 +

AFF1 +


FLT3 +



MLF1 +

NPM1 +

RPN1 +

Disease Details

Therapy-Related AML and MDS, Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome, Acute Myeloid Leukaemias and Myelodysplastic Syndromes, Therapy-Related
Therapy-Related Malignant Neoplasm
Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, and Therapy-Related Myelodysplastic/Myeloproliferative Neoplasm
OncoTree Name
Therapy-Related Myeloid Neoplasms
OncoTree Code


1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.